Related references
Note: Only part of the references are listed.EZH2: biology, disease, and structure-based drug discovery
Jin-zhi Tan et al.
ACTA PHARMACOLOGICA SINICA (2014)
Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis
Sutapa Ray et al.
CELLULAR SIGNALLING (2014)
Critical Role for Lysine 685 in Gene Expression Mediated by Transcription Factor Unphosphorylated STAT3
Maupali Dasgupta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
STAT3: An Anti-Invasive Factor in Colorectal Cancer?
Petrus Rudolf de Jong et al.
CANCERS (2014)
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Ailian Xiong et al.
CANCERS (2014)
Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
Eunhee Kim et al.
CANCER CELL (2013)
Activation of STAT3 in Human Gastric Cancer Cells via Interleukin (IL)-6-Type Cytokine Signaling Correlates with Clinical Implications
Zhengguang Wang et al.
PLOS ONE (2013)
STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor
Yuxin Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Interleukin-6 signaling pathway in targeted therapy for cancer
Yuqi Guo et al.
CANCER TREATMENT REVIEWS (2012)
PRC2 directly methylates GATA4 and represses its transcriptional activity
Aibin He et al.
GENES & DEVELOPMENT (2012)
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Camille Simon et al.
GENES & DEVELOPMENT (2012)
A complex Polycomb issue: the two faces of EZH2 in cancer
Hanno Hock
GENES & DEVELOPMENT (2012)
EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex
Ji Min Lee et al.
MOLECULAR CELL (2012)
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Panagiotis Ntziachristos et al.
NATURE MEDICINE (2012)
Lysine methylation of promoter-bound transcription factors and relevance to cancer
George R. Stark et al.
CELL RESEARCH (2011)
STAT3 Expression, Molecular Features, Inflammation Patterns, and Prognosis in a Database of 724 Colorectal Cancers
Teppei Morikawa et al.
CLINICAL CANCER RESEARCH (2011)
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Shuet Theng Lee et al.
MOLECULAR CELL (2011)
Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes
Jinbo Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Polycomb group protein-mediated repression of transcription
Lluis Morey et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Mechanisms of Polycomb gene silencing: knowns and unknowns
Jeffrey A. Simon et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells
Bin Shi et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
STAT3 as a central mediator of neoplastic cellular transformation
David A. Frank
CANCER LETTERS (2007)
STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen
S Ray et al.
GASTROENTEROLOGY (2005)
Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation
R Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Stat3 dimerization regulated by reversible acetylation of a single lysine residue
ZL Yuan et al.
SCIENCE (2005)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)